• 1. Excellent kinetics of single-phase Gd-doped ceria fuel electrodes in solid oxide cells?
  Andreas Nenning,Manuel Holzmann,Jürgen Fleig,Alexander K. Opitz Mater. Adv., 2021,2, 5422-5431
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Evolving better nanoparticles: Genetic algorithms for optimising cluster geometries
  Dalton Trans., 2003, 4193-4207
• 4. Excitation dependent bidirectional electron transfer in phthalocyanine-functionalised MoS2 nanosheets?
  Christopher J. Harrison,Kyle J. Berean,Enrico Della Gaspera,Jian Zhen Ou,Richard B. Kaner,Kourosh Kalantar-zadeh,Torben Daeneke Nanoscale, 2016,8, 16276-16283
• 5. Excimer emission and magnetoluminescence of radical-based zinc(ii) complexes doped in host crystals?
  Shojiro Kimura,Tetsuro Kusamoto Chem. Commun., 2020,56, 11195-11198

1-Propanone, 1-(4-fluoro-3-methoxyphenyl)- (CAS No. 82846-20-6): A Comprehensive Overview

1-Propanone, 1-(4-fluoro-3-methoxyphenyl)-, identified by its CAS number 82846-20-6, is a fluorinated aromatic ketone that has garnered significant attention in the field of pharmaceutical chemistry and bioorganic synthesis. This compound, characterized by its unique structural features, exhibits promising properties that make it a valuable intermediate in the development of novel therapeutic agents.

The molecular structure of 1-propanone, 1-(4-fluoro-3-methoxyphenyl)- consists of a propanone backbone substituted with a 4-fluoro-3-methoxyphenyl group. This arrangement imparts distinct electronic and steric properties to the molecule, which are highly relevant in medicinal chemistry. The presence of both fluorine and methoxy groups enhances the lipophilicity and metabolic stability of the compound, making it an attractive candidate for further derivatization and drug development.

In recent years, there has been a growing interest in fluorinated aromatic compounds due to their enhanced binding affinity and improved pharmacokinetic profiles. Studies have demonstrated that the introduction of fluorine atoms into biological molecules can lead to increased metabolic stability, reduced susceptibility to enzymatic degradation, and improved cell membrane penetration. These attributes are particularly valuable in the design of small-molecule drugs targeting receptors and enzymes involved in critical biological pathways.

The synthesis of 1-propanone, 1-(4-fluoro-3-methoxyphenyl)- involves multi-step organic transformations that highlight the compound's synthetic versatility. One common synthetic route includes the condensation of acetone with a fluorinated aromatic aldehyde derivative under basic conditions, followed by methylation to introduce the methoxy group. This approach leverages classical organic reactions such as aldol condensation and nucleophilic substitution, showcasing the compound's accessibility through well-established synthetic methodologies.

The pharmacological potential of 1-propanone, 1-(4-fluoro-3-methoxyphenyl)- has been explored in various preclinical studies. Its structural motif is reminiscent of known bioactive molecules, suggesting potential applications in areas such as central nervous system (CNS) disorders, oncology, and anti-inflammatory therapies. For instance, fluorinated aromatic ketones have been investigated for their role as scaffolds in the development of neuroprotective agents due to their ability to modulate neurotransmitter systems.

Recent advancements in computational chemistry have further facilitated the rational design of derivatives based on 1-propanone, 1-(4-fluoro-3-methoxyphenyl)-. Molecular docking studies have identified key interactions between this compound and target proteins, providing insights into its mechanism of action. These computational approaches complement experimental efforts by predicting binding affinities and optimizing lead structures for improved therapeutic efficacy.

The role of fluorine in modulating drug-receptor interactions is well-documented. The electron-withdrawing nature of fluorine can enhance hydrogen bonding interactions with polar residues in proteins, while its lipophilic character improves solubility in lipid environments. This dual functionality makes fluorinated compounds particularly suitable for designing drugs with enhanced bioavailability and target specificity.

In conclusion, 1-propanone, 1-(4-fluoro-3-methoxyphenyl)- (CAS No. 82846-20-6) represents a promising scaffold for pharmaceutical innovation. Its unique structural features and favorable physicochemical properties position it as a valuable building block for the development of next-generation therapeutics. Continued research into this compound and its derivatives is expected to yield significant advancements in drug discovery and medicinal chemistry.

• 586-22-1(1-(3-Fluoro-4-methoxyphenyl)propan-1-one)
• 71292-82-5(3',5'-Difluoro-4'-methoxypropiophenone)
• 64287-19-0(4'-Fluoro-3'-methoxyacetophenone)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)